December 10, 2024, 7:00 PM UTC
[](mailto:mmuller84@bloomberg.net)
Eli Lilly & Co. will begin studies to see if its blockbuster weight-loss medicines are also effective at controlling addictive behaviors like alcohol abuse, smoking and drug addiction, Chief Executive Officer Dave Ricks said.
The drugs are “anti-hedonics,” Ricks said during an interview with David Rubenstein at a meeting of the Economics Club in Washington, DC, and may offer patients respite from their dependence. Some doctors already swear by the shots to help ease cravings, and Lilly’s rival Novo Nordisk A/S said earlier this year it was also planning studies in addiction.
“These medicines can be useful for other things ...
AI-powered legal analytics, workflow tools and premium legal & business news.
Log in to keep reading or access research tools.
© 2024 Bloomberg Industry Group, Inc.